FindTrial
Sign In

The correlation between lncRNA FTX/miR-23b-3p and the occurrence and prognosis of neuropathic pain

The correlation between lncRNA FTX/miR-23b-3p and the occurrence and prognosis of neuropathic pain

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080545
Enrollment
Unknown
Registered
2024-01-31
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic Pain

Interventions

NP group:None
Control group:None

Sponsors

Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. All meet the diagnostic criteria for neuropathic pain; 2. Visual Analog Scale (VAS) score for pain>4 points

Exclusion criteria

Exclusion criteria: 1. Severe heart, liver, and lung dysfunction; 2. Those with mental disorders or abnormal thinking and expression abilities; 3. Locally infected individuals; 4. Hematological diseases or coagulation disorders; 5. Allergy to the drugs used in this study.

Design outcomes

Primary

MeasureTime frame
Inc RNA FTX;miRNA-23b-3p;GSK-3ß;—

Secondary

MeasureTime frame
IL-6;IL-12;TNF-a;—

Countries

China

Contacts

Public ContactLing Qiu

Affiliated Hospital of Southwest Medical University

1575327262@qq.com+86 187 8306 8433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026